A B Figure S1 A B Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications C D Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications E F Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications G H Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications Figure S2 A B Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications C Share No Share 1 or more Indications Indications Figure S3 A B Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications C Share No Share 1 or more Indications Indications Figure S4 A Share No Share 1 or more Indications Indications Figure S5 A Precision−Recall − P: 23840, N: 1299623 1.0 0.8 0.6 CATNIP AUPRC = 0.189 Precision Random AUPRC = 0.0184 0.4 AUPRC = 0.189 AUPRC Rand = 0.0184 0.2 0.0 0.0 0.2 0.4 0.6 0.8 1.0 Recall Figure S6 Mental Disorder Skin Cancer Lung Cancer A B C Percent of Drugs in Percent of Drugs in Percent of Drugs in Class Approved for Class Approved for Class Approved for Indication Indication Indication Location Shift Location Shift Location Shift Breast Cancer Thryoid Cancer Large Intestine Cancer D E F Percent of Drugs in Percent of Drugs in Percent of Drugs in Class Approved for Class Approved for Class Approved for Indication Indication Indication Location Shift Location Shift Location Shift Upper Aerodigestive tract Cancer Gastric Cancer Renal Cancer G H I Percent of Drugs in Class Approved for Percent of Drugs in Percent of Drugs in Indication Class Approved for Class Approved for Indication Indication Location Shift Location Shift Location Shift Figure S7 Urinary Tract Cancer Endometrium Cancer A B Pleura Cancer C Percent of Drugs in Percent of Drugs in Class Approved for Percent of Drugs in Class Approved for Indication Class Approved for Indication Indication Location Shift Location Shift Location Shift Ovarian Cancer Bone Cancer D E Pancreatic Cancer F Percent of Drugs in Percent of Drugs in Percent of Drugs in Class Approved for Class Approved for Class Approved for Indication Indication Indication Location Shift Location Shift Location Shift Oesophagus Cancer Lymphoma/Leukemia Autonomic Ganglia Cancer G H I Percent of Drugs in Percent of Drugs in Class Approved for Percent of Drugs in Class Approved for Indication Class Approved for Indication Indication Location Shift Location Shift Location Shift Figure S8 A Drug Pair Types Kinase Inhibitor & Drug approved for disease Kinase Inhibitor & Drug not approved for disease A Drug Pair Types Dopamine Antagonist & Drug approved for disease Dopamine Antagonist & Drug not approved for disease Figure S9 A Benzatropine & Trimipramine Rotigotine & Trimipramine CATNIP Score CATNIP Dierence in Dierence Figure S10 A 20 B 6 15 4 10 Overlap of Shared kegg Overlap Overlap of Shared reactome Overlap 2 5 0 0 METIXENE ● ● ● BENZATROPINE ● ● BENZATROPINE ● ● ● ATROPINE ● ● ATROPINE ● ● ● ● METIXENE ● ● PERGOLIDE ● ● ● PERGOLIDE ● ● AMITRIPTYLINE ● ● ● ● ● ● ● AMITRIPTYLINE ● ● ● ● 40 30 20 10 0 9 6 3 0 Set Size Set Size C D 40 15 30 10 20 Overlap of Shared mf Overlap Overlap of Shared reactome Overlap 5 10 0 0 METIXENE ● ● ● ● GLICLAZIDE ● PERGOLIDE ● ● ● ● ● ATROPINE ● ● ● ● ● ● ● BENZATROPINE ● ● ● ● ● VANDETANIB ● ● AMITRIPTYLINE ● ● ● ● ● ● ● ● ● ● ● 100 75 50 25 0 20 15 10 5 0 Set Size Set Size E F 30 15 20 10 Overlap of Shared mf Overlap Overlap of Shared kegg Overlap 10 5 0 0 GLICLAZIDE ● GLICLAZIDE ● VANDETANIB ● ● VANDETANIB ● ● 25 20 15 10 5 0 40 20 0 Set Size Set Size Figure S10 Table S1 Table S2.